Vecuronium
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Vecuronium: From Neuromuscular Blockade in Anaesthesia to insomnia (disease)
One-Sentence Summary
Vecuronium is a non-depolarising neuromuscular blocker. Its approved indication text is not available in the data compiled for this report, but it is used as a muscle relaxant in general anaesthesia. The TxGNN model predicts it may be effective for insomnia, but there is only 1 registered clinical trial (a generic paediatric pharmacokinetics study with no insomnia endpoint) and no publications supporting this direction. The prediction is best read as a model artefact rather than a credible repurposing signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the licence records (approved indication text is empty) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 0.9934 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, vecuronium blocks nicotinic acetylcholine receptors at the neuromuscular junction. This produces skeletal muscle relaxation during surgery and intubation.
The mechanistic link to insomnia is weak. Vecuronium has no sedative, hypnotic or central nervous system activity. The high TxGNN score (0.9934) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Other top-ranked predictions show the same pattern. These include irritable bowel syndrome, neurocirculatory asthenia, benign prostatic hyperplasia, cauda equina syndrome, headache disorder, rhinitis, anxiety, trigeminal autonomic cephalalgia and migraine disorder. None has a plausible mechanism, and most have no direct evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01431326 | N/A | Completed | 3520 | Paediatric pharmacokinetics of understudied drugs given as standard of care. It does not test vecuronium for insomnia and provides no efficacy evidence. |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 240575 | Verbo 4mg Injection | Vial of 1 injection | Not stated |
| 118323 | Kabivec 4mg Injection | Vial of 2 ml injection | Not stated |
| 202741 | Samvec 4mg Injection | Vial of 2 ml injection | Not stated |
| 235167 | Vecuron 10mg Injection | Vial of 10 ml injection | Not stated |
| 236872 | Vecurofix 10 Injection | Vial of 1 injection | Not stated |
There are 20 valid single-ingredient registrations in total, all injectable. Only the first five are listed here.
Safety Considerations
- Drug Interactions: The interaction screening returned 85 interacting drugs. Notable Major interactions include:
- Paromomycin
- Kanamycin
- Neomycin
Moderate interactions include:
- Aminoglycoside and tetracycline-class antibiotics (doxycycline, tetracycline, minocycline)
- Vancomycin
- Amphotericin B
- Corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, prednisone)
- Magnesium salts
- Mannitol
- Metoclopramide
Minor interactions include ranitidine.
Please refer to the package insert for warnings and contraindications.
Because vecuronium paralyses muscles without causing sedation, using it outside a monitored anaesthetic setting carries serious risks, including patient distress and awareness.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (L5). There are no trials or literature supporting efficacy in insomnia, and vecuronium has no sedative or hypnotic activity. The apparent signal likely comes from its co-use with sedatives during anaesthesia.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Indian regulator
- Mechanism of action data
- Any plausible mechanistic or preclinical rationale linking neuromuscular blockade to sleep regulation
- A safety assessment of using a paralysing agent outside the anaesthetic setting
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.